Hugh D Mai, MD
Gastroenterology · San Jose
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- California licence: Delinquent
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Mai’s office at (408) 993-0636 to ask if they take your plan before you enroll.
California Medical Board record
Licence A45865 · Delinquent
Licence status: Delinquent · since 1989 · expires 2022-04-30 · University of Texas Medical School at San Antonio.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$1,965 in 2021
Medicaid paid $1,965 for 33 billed services this clinician did in 2021, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 33 | $1,965 |
| 2021 | 33 | 1 | 16 | $1,965 |
| 2020 | 31 | 1 | 18 | $2,234 |
See the largest Medicaid services in earlier years
2020
| Short return visit (20+ min) | 31 | $2,234 |
Money from drug and device companies
$36 in 2022
| 2022 | 1 | 2 | None | $36 |
| 2021 | 7 | 8 | None | $145 |
| 2020 | 8 | 10 | None | $163 |
| 2019 | 9 | 34 | None | $724 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Stelara | $36 | 2 payments
|
See all 2 published payments
| Janssen Biotech | Meals · 2022-06-13 | Stelara | $12 |
| Janssen Biotech | Meals · 2022-06-13 | Stelara | $24 |
See earlier years (2021, 2020, 2019)
2021: $145
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $41 | 2 payments
|
| QOL Medical | Sucraid | $23 | 1 payment
|
| AbbVie | Mavyret | $22 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $17 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $15 | 1 payment
|
| Ambu | None | $14 | 1 payment
|
| Nestle HealthCare Nutrition | Zenpep | $13 | 1 payment
|
2020: $163
| AbbVie | Mavyret | $44 | 3 payments
|
| Gilead Sciences | None | $30 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $20 | 1 payment
|
| RedHill Biopharma | Talicia | $18 | 1 payment
|
| Braintree Laboratories | Suprep Bowel Prep | $15 | 1 payment
|
| Merck Sharp & Dohme | Renflexis | $13 | 1 payment
|
| Allergan | Zenpep | $12 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $11 | 1 payment
|
2019: $724
| AbbVie | Humira | $202 | 16 payments
|
| Boston Scientific | Acquire | $118 | 1 payment
|
| Endogastric Solutions | Esophyx | $110 | 1 payment
|
| Gilead Sciences | Epclusa | $77 | 4 payments
|
| Merck Sharp & Dohme | Dificid | $72 | 4 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $59 | 3 payments
|
| Shionogi | Mulpleta | $44 | 2 payments
|
| Ferring Pharmaceuticals | Clenpiq | $29 | 2 payments
|
| Allergan | Linzess | $13 | 1 payment
|
Professional record
- NPI
- 1710921903
- Licence
- CA A45865California A45865: Delinquent · expires 2022-04-30
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 25 N 14th St, Suite 620, San Jose, CA, 95112
- NPI first listed
- 2006-06-16
- NPI last updated
- 2013-07-18
This is when the NPI record was last certified, not a medical board exam.